Buy Rating Affirmed: ZyVersa Therapeutics’ Promising Pipeline and Strategic Advancements

Analyst Ed Arce of H.C. Wainwright maintained a Buy rating on ZyVersa Therapeutics (ZVSA – Research Report), with a price target of $12.00.

Ed Arce has given his Buy rating due to a combination of factors related to the potential of ZyVersa Therapeutics’ pipeline products and strategic milestones. The company’s VAR 200 program shows promise as a disease-modifying treatment for diabetic kidney disease (DKD), with a mechanism that actively and passively mediates cholesterol efflux, potentially reducing proteinuria and kidney injury. Given the global prevalence of DKD and the lack of current treatments that go beyond delaying disease progression, the initiation of the Phase 2a proof-of-concept study for VAR 200 represents a significant step forward for the company and the treatment landscape.

Additionally, ZyVersa’s IC 100 inflammasome inhibitor is slated to enter clinical trials by the end of 2024, targeting a range of inflammatory disorders through its novel mechanism of action. This program’s potential to become a leading clinical-stage inflammasome inhibitor further underpins the Buy rating. The upcoming shareholder meeting to vote on a reverse stock split demonstrates the company’s proactive steps to comply with Nasdaq listing requirements and supports investor confidence. These developments, combined with the anticipated clinical advancements, provide a strong basis for Ed Arce’s positive outlook on ZyVersa Therapeutics’ stock.

According to TipRanks, Arce is a 5-star analyst with an average return of 11.2% and a 42.00% success rate. Arce covers the Healthcare sector, focusing on stocks such as Travere Therapeutics, Ultragenyx Pharmaceutical, and Talphera.

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

ZyVersa Therapeutics (ZVSA) Company Description:

Larkspur Health Acquisition Corp is a blank check company.